References
- American Diabetes Association. Fast facts: data and statistics about Diabetes [Internet]; 2014 [cited 2015 Jul 27]. Available from: http://professional.diabetes.org/admin/UserFiles/0%20-%20Sean/Documents/Fast_Facts_9-2015.pdf.
- International Diabetes Federation. Diabetes facts and figures [Internet]. IDF Diabetes Atlas Sixth Edition Update; 2014 [cited 2015 Jul 27]. Available from: https://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures.
- Janssen Pharmaceuticals. Product Package prepared by Janssen. Product information. Invokana full prescribing information. Titusville (NJ); 2015.
- Guthrie RM. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med. 2013;125(3):21–32.
- Wilding JPH, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29(3):438–444.
- Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertension. 2014;16(12):875–882.
- Guthrie RM. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgrad Med. 2015;127(5):463–479.